• In the past quarter, Adaptive Biotechnologies reported first‑quarter 2026 revenue of US$70.87 million, up from US$52.44 million a year earlier, while narrowing its net loss to US$20.03 million and reducing basic loss per share from US$0.20 to US$0.13.
• The results were powered by Minimal Residual Disease testing, with clonoSEQ volumes rising strongly and management raising full‑year 2026 MRD revenue guidance to US$260–US$270 million, underscoring the segment’s growing importance to the business.
• Now we’ll consider how this strong MRD growth and upgraded 2026 guidance may influence Adaptive Biotechnologies’ longer‑term investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Adaptive Biotechnologies Investment Narrative Recap

To own Adaptive Biotechnologies, you need to believe its Minimal Residual Disease testing can support a path toward smaller losses at the company level. The latest quarter reinforced MRD as the core growth driver and slightly eased the near term profitability risk, but the business is still loss making and exposed to execution risk around MRD adoption and pricing.

Among recent developments, the termination of the Genentech collaboration, effective February 9, 2026, now looks more important in light of Q1 results. With Immune Medicine revenue already down sharply, the raised 2026 MRD guidance to US$260–US$270 million matters even more, because it needs to offset the loss of that partnership driven income and support the broader investment case.

Yet, even with strong MRD momentum, investors should be aware that prolonged company wide unprofitability could still lead to...

Adaptive Biotechnologies’ narrative projects $415.3 million revenue and $64.0 million earnings by 2029. This requires 14.5% yearly revenue growth and a $123.5 million earnings increase from -$59.5 million today.

Uncover how Adaptive Biotechnologies' forecasts yield a $20.57 fair value, a 49% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming about 17 percent annual revenue growth and a swing to roughly US$9.9 million in earnings, so this MRD driven beat may either support their view or force a rethink, depending on how you weigh the ongoing partnership and profitability risks.

Explore 3 other fair value estimates on Adaptive Biotechnologies - why the stock might be worth as much as 75% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Adaptive Biotechnologies research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Adaptive Biotechnologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Adaptive Biotechnologies' overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.